Skip to main content

Table 2 Provision of proven efficacious therapies in patients with CAD, multi-centre studies since 1995

From: A randomized trial to assess the impact of opinion leader endorsed evidence summaries on the use of secondary prevention strategies in patients with coronary artery disease: the ESP-CAD trial protocol [NCT00175240]

Setting (ref)

Sample Size

Statin Use

ACE InhibitorUse

Beta-blockerUse

Antiplatelet Use

Current Smokers

% with cholesterol at or below target*

Audits from General Practices:

Canada (42)

4315

38%

NR

NR

53%

25%

14%

Canada (43)

NR

NR

NR

NR

54%

NR

NR

USA (46)

11 745

NR

NR

21%

NR

NR

NR

UK (41)

1921

NR

10%

32%

63%

18%

17%

UK (44)

24 431

16%

13%

22%

50%

24%

56%

Canada (49)

3721

100%

NR

NR

NR

17%

73%

International REACH Registry (50)

40 258

76%

51%

63%

86%

13%

NR

Audits in patients discharged after acute myocardial infarction or coronary artery bypass surgery:

USA (39)

201 752

NR

30%

34%

83%

NR

NR

USA (37)

1710

12%

NR

44%

53%

NR

NR

USA (38)

622

37%

NR

23%

46%

25%

15%

USA (45)

190 015

NR

31%

NR

NR

NR

NR

USA (47)

25 000

NR

NR

NR

81%

NR

NR

Europe (40)

3379

58%

43%

66%

84%

21%

41%

Ontario(48)

9667

40%

65%

68%

NR

NR

NR

Quebec(48)

4790

43%

57%

68%

NR

NR

NR

British Columbia(48)

2570

42%

58%

61%

NR

NR

NR

Nova Scotia(48)

761

36%

58%

83%

NR

NR

NR

Alberta (APPROACH patients)**

5104

34%

39%

61%

81%

NR

NR

  1. Note that while the general practice audits represent cross-sectional data at varying times after the diagnosis of CAD, the audits in patients discharged after acute MI generally represent prescribing data between 90 days and 120 days after MI.
  2. * Target cholesterol defined as LDL cholesterol ≤ 2.6 mmol/L or total cholesterol ≤ 5.0 mmol/L.
  3. ** Medications in use at the time of the cardiac catheterization (no data available on prescriptions in follow-up). [Colleen Norris, personal communication, August 2003]